Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT00625846
Show Display Options
Rank Status Study
1 Active, not recruiting Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
Conditions: Recurrent Thyroid Gland Carcinoma;   Stage III Differentiated Thyroid Gland Carcinoma;   Stage III Thyroid Gland Medullary Carcinoma;   Stage IVA Differentiated Thyroid Gland Carcinoma;   Stage IVA Thyroid Gland Medullary Carcinoma;   Stage IVA Thyroid Gland Undifferentiated (Anaplastic) Carcinoma;   Stage IVB Differentiated Thyroid Gland Carcinoma;   Stage IVB Thyroid Gland Medullary Carcinoma;   Stage IVB Thyroid Gland Undifferentiated (Anaplastic) Carcinoma;   Stage IVC Differentiated Thyroid Gland Carcinoma;   Stage IVC Thyroid Gland Medullary Carcinoma;   Stage IVC Thyroid Gland Undifferentiated (Anaplastic) Carcinoma;   Thyroid Gland Undifferentiated (Anaplastic) Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride

Study has passed its completion date and status has not been verified in more than two years.